The FDA promptly shot down the company’s bid for an EDS with idiopathic hypersomnia (IH) indication with a Refusal to File (RTF) letter after a missed phase 3 study. While Wakix (pitolisant ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback